Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)Stefaan van Gool ist Herausgeber einer Sonderausgabe im Journal of Molecular Sciences
/in Brain Tumors in Children, IOZK Aktuelles, IOZK Veröffentlichungen /von IOZKCounteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
/in International Publications, IOZK Veröffentlichungen /von 2022-10-27 / Int J Mol Sci 2022 Oct;23(21)Poster presentation at the annual meeting of the Association for Cancer Immunotherapy
/in Glioblastoma, International Publications, IOZK bei Fachtagungen, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)Poster presentation at the International Symposium on Pediatric Neuro-Oncology
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2022-02-28 / Biomedicines 2022 Feb;10(3)Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
/in International Publications, IOZK Veröffentlichungen /von 2021-07-04 / Cancer Immunol Immunother 2021 Jul;DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2021-02-25 / Neuro Oncol 2021 02;23(2):240-250Impaired DNA repair in mouse monocytes compared to macrophages and precursors
/in International Publications, IOZK Veröffentlichungen /von 2020-12-30 / DNA Repair (Amst) 2020 Dec;98:103037
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Neue IOZK Veröffentlichung zum Thema Liquid Biopsy
- Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
- Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines